DMAC (DiaMedica Therapeutics) Tariff Resilience Score: 6/10 (As of Jun. 25, 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $6.36
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Tariff Resilience Score?

DiaMedica Therapeutics DMAC +1.75% 31 Tariff Resilience Score is 6 as of Jun. 25, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,379 Biotechnology companies, DiaMedica Therapeutics ranks better than 75.92% on this metric.

DiaMedica Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

DiaMedica Therapeutics has DMAC relies on international suppliers for some raw materials, but its primary market is North America. Past tariffs have had moderate impact, but the company has diversified suppliers and some pricing power. The biotech industry often benefits from specific tariff exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes DiaMedica Therapeutics might have Average Resilient.

DiaMedica Therapeutics  (NAS:DMAC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

DiaMedica Therapeutics Tariff Resilience Score Related Terms

DMAC vs BCYC, RZLT, ABEO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Tariff Resilience Score falls into.


DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
DiaMedica Therapeutics (DMAC) has a Tariff Resilience Score of 6 as of Jun. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, DiaMedica Therapeutics ranks #332 out of 1379 companies in the Biotechnology industry, placing it in the top 24.1%.
Is DiaMedica Therapeutics' Tariff Resilience Score too high?
DiaMedica Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. DiaMedica Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, DiaMedica Therapeutics ranks #332 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Tariff Resilience Score compare to BCYC and RZLT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #332 out of 1379 companies for Tariff Resilience Score. This places DiaMedica Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. DiaMedica Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DiaMedica Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Tariff Resilience Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.36
Price